By: IPP Bureau
Last updated : May 21, 2026 8:00 am
Domestic formulations business posts double-digit growth as insulin and GLP portfolios drive strong FY26 performance
Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, has reported robust growth in revenue and profitability during FY26.
For Q4 FY26, the company reported consolidated revenue from operations of Rs. 757 crore, registering a 7 per cent year-on-year growth compared to Rs. 705 crore in the corresponding quarter last year. Gross profit stood at Rs. 571 crore, up 7 per cent YoY.
EBITDA for the quarter increased 8 per cent to Rs. 274 crore from Rs. 252 crore in Q4 FY25, with EBITDA margin improving to 36.2 per cent.
Profit after tax (PAT) witnessed a sharp 173 per cent rise to Rs. 279 crore during the quarter, compared to Rs. 102 crore in the year-ago period. PAT margin expanded significantly to 36.9 per cent.
For the full financial year FY26, consolidated revenue from operations rose 8 per cent to Rs. 3,129 crore against Rs. 2,894 crore in FY25. EBITDA increased 10 per cent to Rs. 1,120 crore, while PAT surged 73 per cent to Rs. 648 crore.
The company’s Domestic Branded Formulations (DBF) business recorded 12 per cent YoY revenue growth in Q4 FY26 and 11 per cent growth for the full year, with EBITDA margin at 37 per cent.
Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, “Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBIDTA growth and industry leading EBIDTA margin of 37%.”
“Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%. Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space,” added Bakshi.